3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Smoldering Multiple Myeloma
1
Interventions
Specimen Handling
132
Magnetic Resonance Spectroscopy
107
Biopsy
79
pembrolizumab
66
Nivolumab
63
Carboplatin
62
Cisplatin
60
Cyclophosphamide
56
Paclitaxel
47
Radiotherapy
37
Gemcitabine
37
Bevacizumab
36
Dexamethasone
33
Pemetrexed
28
Rituximab
27
Fluorouracil
27
Doxorubicin
26
olaparib
25
Injections
25
fludarabine
24
durvalumab
24
atezolizumab
24
Radiation
24
Ipilimumab
23
Docetaxel
23
Oxaliplatin
22
Cytarabine
22
venetoclax
21
Vincristine
21
Taxes
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
IPH-2101
×
30 days
×
Clear all
NCT01222286
2026-05-14
KIRMONO
Innate Pharma
Phase 2
Completed
30 enrolled
10 charts